JP2016519107A - Ｔｈ−３０２抗癌療法のための予測および応答のバイオマーカー - Google Patents

Ｔｈ−３０２抗癌療法のための予測および応答のバイオマーカー Download PDF

Info

Publication number
JP2016519107A
JP2016519107A JP2016507634A JP2016507634A JP2016519107A JP 2016519107 A JP2016519107 A JP 2016519107A JP 2016507634 A JP2016507634 A JP 2016507634A JP 2016507634 A JP2016507634 A JP 2016507634A JP 2016519107 A JP2016519107 A JP 2016519107A
Authority
JP
Japan
Prior art keywords
cancer
patient
hypoxia
predetermined value
degree
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016507634A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016519107A5 (enExample
Inventor
ハート，チャールズ
イー． セリック，ハロルド
イー． セリック，ハロルド
サン，ジェシカ
Original Assignee
スレッショルド ファーマシューティカルズ，インコーポレイテッド
スレッショルド ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スレッショルド ファーマシューティカルズ，インコーポレイテッド, スレッショルド ファーマシューティカルズ，インコーポレイテッド filed Critical スレッショルド ファーマシューティカルズ，インコーポレイテッド
Publication of JP2016519107A publication Critical patent/JP2016519107A/ja
Publication of JP2016519107A5 publication Critical patent/JP2016519107A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016507634A 2013-04-10 2014-04-09 Ｔｈ−３０２抗癌療法のための予測および応答のバイオマーカー Pending JP2016519107A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361810643P 2013-04-10 2013-04-10
US61/810,643 2013-04-10
PCT/US2014/033491 WO2014169035A1 (en) 2013-04-10 2014-04-09 Predictive and response biomarker for th-302 anti-cancer therapy

Publications (2)

Publication Number Publication Date
JP2016519107A true JP2016519107A (ja) 2016-06-30
JP2016519107A5 JP2016519107A5 (enExample) 2017-06-01

Family

ID=51689977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016507634A Pending JP2016519107A (ja) 2013-04-10 2014-04-09 Ｔｈ−３０２抗癌療法のための予測および応答のバイオマーカー

Country Status (4)

Country Link
US (1) US20160296538A1 (enExample)
EP (1) EP2983591A4 (enExample)
JP (1) JP2016519107A (enExample)
WO (1) WO2014169035A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
CN107427515B (zh) 2014-12-03 2021-11-16 奥克兰联合服务有限公司 用于治疗癌症的激酶抑制剂前药
US11504075B2 (en) * 2017-12-20 2022-11-22 University Health Network System, methods, and devices for calculating hypoxic fraction and equilibration rate of small molecular weight tracers using dynamic imaging
WO2023025291A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
JP7762796B2 (ja) 2021-08-27 2025-10-30 アセンタウィッツ ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
EP4509127A4 (en) 2022-04-15 2026-07-15 Ascentawits Pharmaceuticals Ltd CANCER TREATMENT METHOD USING TH-302 ALONE OR IN COMBINATION WITH A PARP INHIBITOR
EP4529926A4 (en) 2022-05-23 2026-07-01 Ascentawits Pharmaceuticals Ltd CANCER TREATMENT METHOD BY COMBINATION OF AN ALKYLATING AGENT PRODRUGATION AND A CELL CYCLE INHIBITOR
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
EP4674418A1 (en) 2023-02-27 2026-01-07 Ascentawits Pharmaceuticals, Ltd. Solution, freeze-dried formulation, freeze-dried formulation unit package, injection, and injection preparation method
EP4755396A1 (en) 2023-07-28 2026-06-10 Ascentawits Pharmaceuticals, Ltd. Treatment of p53 gene mutation or defect negative cancer and tumor patients
CN121985960A (zh) 2023-10-18 2026-05-05 深圳艾欣达伟医药科技有限公司 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006032A2 (en) * 2010-06-28 2012-01-12 Threshold Pharmaceuticals, Inc. Treatment of blood cancer
WO2012009288A2 (en) * 2010-07-12 2012-01-19 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20070117784A1 (en) * 2005-03-04 2007-05-24 Novacea, Inc. Treatment of hyperproliferative diseases with anthraquinones
WO2010048330A1 (en) * 2008-10-21 2010-04-29 Threshold Pharmaceuticals, Inc. Treatment of cancer using hypoxia activated prodrugs
WO2012008860A2 (en) * 2010-07-16 2012-01-19 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006032A2 (en) * 2010-06-28 2012-01-12 Threshold Pharmaceuticals, Inc. Treatment of blood cancer
WO2012009288A2 (en) * 2010-07-12 2012-01-19 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARLIN, S. & HUMM, J. L.: "PET of hypoxia: current and future perspectives", J. NUCL. MED., vol. 53巻, JPN6017033378, 2012, pages 1171 - 1174, ISSN: 0003633678 *
DUBOIS, L. J. ET AL.: "Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging", PROC. NATL. ACAD. SCI. USA, vol. 108巻35号, JPN6017033376, 2011, pages 14620 - 14625, ISSN: 0003799618 *

Also Published As

Publication number Publication date
EP2983591A4 (en) 2016-12-28
US20160296538A1 (en) 2016-10-13
EP2983591A1 (en) 2016-02-17
WO2014169035A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
EP2983591A1 (en) Predictive and response biomarker for th-302 anti-cancer therapy
Menke-van der Houven et al. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer
Haugen et al. Evolving approaches to patients with advanced differentiated thyroid cancer
Malik et al. Futuristic approach to cancer treatment
Shinchi et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer
CN101001623B (zh) 抗癌效果增强剂
Mukohara et al. Eribulin mesylate in patients with refractory cancers: a Phase I study
JP2021510380A (ja) 放射線感受性組織における細胞保護薬の選択的堆積およびその使用
Li et al. Safety, pharmacokinetic and clinical activity of intrathecal chemotherapy with pemetrexed via the ommaya reservoir for leptomeningeal metastases from lung adenocarcinoma: a prospective phase I study
CN109640985A (zh) Hdac抑制剂和pd-l1抑制剂的组合疗法
Morris et al. A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer
JP2016528217A (ja) 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療
WO2014142220A1 (ja) 抗腫瘍剤
Schmid et al. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma
Moreau et al. Priming the abscopal effect using multifunctional smart radiotherapy biomaterials loaded with immunoadjuvants
Edelman et al. Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors
JP2022519923A5 (enExample)
Nishikawa et al. A case treated with nivolumab after small cell lung cancer transformation of mutant EGFR non-small cell lung cancer
Sonoda et al. EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
Vansteenkiste et al. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model
Zheng et al. Longitudinal tumor hypoxia imaging with [18F] FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity
Gutierrez et al. A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL)
Maruyama et al. Therapeutic strategy for the treatment of postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy of radiotherapy
JP6656484B2 (ja) 放射性抗腫瘍剤
Willett et al. Radiation therapy in stage II and III rectal cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170403

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180521